SF3B1 mutations resulting in simultaneous defects in splicing and tRNA/ribosome stability may expose a unique vulnerability to dual targeting using 8-azaguanine, providing a therapeutic opportunity for MDS with SF3B1 mutations (63). This evidence concerns the gene SF3B1 and myelodysplastic syndrome.